PKTXX
Undisclosed
DiscoveryActive
Key Facts
About PepKon
PepKon is a preclinical-stage biotech leveraging a proprietary peptide platform to develop agonists targeting the TSP-1/CD47 pathway for cancer treatment. Its lead program, PKT16, has shown promising in vitro and preclinical efficacy in refractory chronic lymphocytic leukemia (CLL) and select solid tumors, with plans to enter first-in-human trials around 2025. The company is built on over a decade of academic research, is led by a team with pharmaceutical development expertise, and is funded through private and public sources. PepKon's approach aims to overcome limitations of current therapies by selectively inducing immunogenic cell death in cancer cells while sparing healthy tissues.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |